BioSpace News Archive

Dental composites are types of synthetic resins used in dentistry as a restorative material or adhesives. Dental composites have certain properties which benefit patients according to the cavity.

Pompe disease is a genetic mutation that generally occurs in infants. In this condition, the body is unable to produce a specific enzyme that is responsible for breaking glycogen into a simple sugar.

Dassault Systèmes joins a growing group of companies that are setting emissions reduction targets in line with what climate science says is necessary

Aurinia Pharmaceuticals Inc. announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference.

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration has granted Fast Track designation for remestemcel-L in the treatment of acute respiratory distress syndrome due to COVID-19 infection.

Led by Rock Springs Capital with participation by funds and accounts advised by T. Rowe Price Associates, Inc., Andreessen Horowitz, and other major investors

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has entered into an agreement to amend certain key terms of its Royalty-Backed Loan agreement (“Royalty-Backed Loan”) with HealthCare Royalty Partners (“HCR”). The key terms amended are summarized as follows:   Revised to provide for rep

Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that the first patient has been dosed in the high-dose cohort of the Phase 1/2 (“Stage 1”) study for Type I (infantile) and Type II (late inf

Amicus Therapeutics (Nasdaq: FOLD) today announced the election and appointment of Michael A. Kelly to its Board of Directors. Mr. Kelly is a proven leader with more than two decades of executive experience in the life sciences industry serving in various strategic finance and operations positions, including Chief Financial Officer and board member of multiple biotechnology companies. John F. Crowley, Chairman and Chief Executive Officer of A

Todos Medical (OTCQB: TOMDF) , an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for early detection of cancer and Alzheimer’s disease, today announced $3.2 million in sales for the month of November 2020. This represents a 269% increase in monthly sales as compared with October 2020. The majority o